The present invention relates to a nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof, and a method for preparing the intermediate compound.

This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.

Compounds of formula (I) and its pharmaceutically acceptable salts are described ##STR00001##
wherein R.sub.1, R.sub.2, X, Y, A, B are as defined in the specification. Also disclosed are methods for preparing the compounds of formula (I) or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the compounds of formula (I) or pharmaceutically acceptable salts thereof.

A pharmaceutical or nutraceutical composition, contains a) a core a), containing a pharmaceutical or a nutraceutical active ingredient and b) a coating layer b), containing a mixture of 80 to 96% by weight of a water-insoluble (meth)acrylate polymer and 4 to 20% by weight of guar gum, wherein the water-insoluble (meth)acrylate polymer contains polymerized units of more than 95 and up to 100% by weight C.sub.1-C.sub.4-alkyl esters of acrylic acid or of methacrylic acid and less than 5% by weight of acrylic acid or methacrylic acid.

The present invention relates to a fusion protein binding to a vascular endothelial growth factor (VEGFR) and/or a placental growth factor (PIGF). The fusion protein of the present invention comprises (a) a Fc domain of IgG1, wherein two heavy chains are linked by disulfide bond, and (b) four immunoglobulin domain2s of the VEGFR1, wherein two immunoglobulin domain2s are sequentially fused to each heavy chain of the Fc domain of (a). The present fusion protein has excellent activities of inhibiting cell migration and cell invasion, and has highly enhanced growth inhibition effects to various carcinomas and fibroblasts. Therefore, The fusion protein of the present invention can be used in the preparation of an agent for treating cancers or ocular diseases.

An objet of the present invention is to provide an emulsion composition, a powdery matter and a production method of an emulsion composition, each enabling superior stability of the emulsion.

[Means for Resolution]

An emulsion composition according to one embodiment of the present invention contains a coconut oil, a lecithin and a co-emulsifier. The co-emulsifier is preferably a polyhydric alcohol having at least two hydroxyl groups. The co-emulsifier is preferably propylene glycol, glycerol, sorbitol, xylitol, maltitol, mannitol, glucose, galactose, mannose, lactose, fructose, maltose, sucrose, xylose, trehalose or guar gum. The emulsion composition preferably further contains deionized water. The emulsion composition preferably further contains honey, collagen, inositol, glutathione or potassium sorbate. A powdery matter according to another aspect of the present invention contains a coconut oil, a lecithin and a co-emulsifier. The powdery matter is preferably water soluble.

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.

Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.

The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.